Reims

• PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting
  2023-508531-30-00 4 2024-03-25 grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
• Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients Recruiting
  2024-513328-40-00 6 2024-03-25 Pyelonephritis
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting
  2022-502351-60-00 4 2024-02-22 Patients having a HER2-amplified metastatic breast cancer with evoluti
• Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) Recruiting
  2024-516402-32-00 5 2024-02-13 Adult patients with aHUS associated with HE and severe kidney involvem
• ERASE PH-COPD Recruiting
  2022-500862-93-00 5 2024-02-01 Pulmonary Hypertension
• Trial evaluating the efficacy and the safety of FOLFIRINOX3 treatment in patients with unresectable locally advanced or metastatic pancreati … Recruiting
  2023-505889-29-01 4 2024-02-01 Patients with unresectable locally advanced or metastatic pancreatic c
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• INduction in Sensitized kidney Transplant recipients without pre-Existing donor-specific AntiboDies: a randomized multicentre trial between … Recruiting
  2022-502007-30-00 5 2023-11-07 Kidney transplant
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 5 2023-10-17 Thromboprophylaxis in good and intermediate prognosis advanced germ ce
• Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren … Recruiting
  2024-512999-35-00 4 2023-06-23 Patients with HER 2 negative locally advanced, recurrent or metastatic
• RIISC Recruiting
  2024-513669-38-00 5 2023-05-17 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial In
• « Effect of sedative and anxiolytic sedation on children experience after general anesthesia » PEDIA_prem study. Recruiting
  2022-501124-23-00 5 2023-04-18 General anesthesia and sedative and anxiolytic sedation
• THINK - intensification of blood pressure lowering Therapeutics based on diuretics versus usual management for uncontrolled Hypertension IN … Recruiting
  2022-501494-39-00 5 2023-03-28 Uncontrolled Hypertension IN patients with moderate to severe chronic
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 4 2023-01-25 ER positive HER2 negative breast cancer
• EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co … Recruiting
  2022-501335-16-00 10 2023-01-16 Interstitial lung disease
• Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing An … Recruiting
  2024-515243-37-00 11 2022-08-21 Kidney Transplantation BKV infection
• VAC-WARTS Recruiting
  2024-513671-40-00 5 2022-06-29 HPV vaccine
• A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte … Recruiting
  2024-515945-40-00 10 2022-05-02 Non small cell lung cancer
• Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting
  2023-508879-36-00 5 2022-04-28 Pruritus
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients Recruiting
  2023-508594-84-00 4 2022-01-11 Metastatic pancreatic adenocarcinoma

Showing 97–120 of 208 trials